SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurogen (NRGN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (255)5/12/2000 12:49:00 PM
From: Jim Oravetz   of 523
 
Neurogen Corp. - 1st Quar March 31:
2000 1999
Revenue $2,841,000 $2,636,000
Net income a (10,669,000) (3,406,000)
Avg shrs (basic) 15,297,000 14,548,000
Avg shrs (diluted) 15,297,000 14,548,000
Shr earns (basic)
Net income a (.70) (.23)
Shr earns (diluted)
Net income a (.70) (.23)
a. Includes a noncash compensation charge of $6.5 million related to the performance of restricted stock previously granted to employees. Excluding charges, losses were $4.17 million, or 27 cents a share.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News